These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17623696)

  • 1. De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia.
    Deslouches B; Gonzalez IA; DeAlmeida D; Islam K; Steele C; Montelaro RC; Mietzner TA
    J Antimicrob Chemother; 2007 Sep; 60(3):669-72. PubMed ID: 17623696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.
    Deslouches B; Islam K; Craigo JK; Paranjape SM; Montelaro RC; Mietzner TA
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3208-16. PubMed ID: 16048927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.
    Chen C; Deslouches B; Montelaro RC; Di YP
    Clin Microbiol Infect; 2018 May; 24(5):547.e1-547.e8. PubMed ID: 28882728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
    Cirioni O; Giacometti A; Ghiselli R; Orlando F; Kamysz W; D'Amato G; Mocchegiani F; Lukasiak J; Silvestri C; Saba V; Scalise G
    J Infect Dis; 2004 Jul; 190(2):356-64. PubMed ID: 15216473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection.
    Papareddy P; Kasetty G; Kalle M; Bhongir RK; Mörgelin M; Schmidtchen A; Malmsten M
    J Antimicrob Chemother; 2016 Jan; 71(1):170-80. PubMed ID: 26503666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia.
    Katoh H; Yasumoto H; Shimizu M; Hamaoka S; Kinoshita M; Akiyama K; Sawa T
    Crit Care Med; 2016 Jan; 44(1):e12-24. PubMed ID: 26317571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.
    Cirioni O; Silvestri C; Ghiselli R; Orlando F; Riva A; Mocchegiani F; Chiodi L; Castelletti S; Gabrielli E; Saba V; Scalise G; Giacometti A
    J Antimicrob Chemother; 2008 Dec; 62(6):1332-8. PubMed ID: 18799470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
    Song Z; Wu H; Mygind P; Raventos D; Sonksen C; Kristensen HH; Høiby N
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3868-74. PubMed ID: 16127064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of Pseudomonas aeruginosa sepsis in mice.
    Pan CY; Chao TT; Chen JC; Chen JY; Liu WC; Lin CH; Kuo CM
    Int Immunopharmacol; 2007 May; 7(5):687-700. PubMed ID: 17386416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns.
    Steinstraesser L; Tack BF; Waring AJ; Hong T; Boo LM; Fan MH; Remick DI; Su GL; Lehrer RI; Wang SC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1837-44. PubMed ID: 12019098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-thanatin in vitro prevents colistin resistance and improves its efficacy in an animal model of Pseudomonas aeruginosa sepsis.
    Cirioni O; Wu G; Li L; Orlando F; Silvestri C; Ghiselli R; Shen Z; Gabrielli E; Brescini L; Lezoche G; Provinciali M; Guerrieri M; Giacometti A
    Peptides; 2011 Apr; 32(4):697-701. PubMed ID: 21262298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
    Cirioni O; Ghiselli R; Silvestri C; Kamysz W; Orlando F; Mocchegiani F; Di Matteo F; Riva A; Lukasiak J; Scalise G; Saba V; Giacometti A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2005-10. PubMed ID: 17403995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The antibacterial effect of cecropin B on pseudomonas aeruginosa infection of wounds in mice].
    Ren HT; Han CM; Zhang R; Xu ZJ; Meng ZQ; Weng HB; Niu BL
    Zhonghua Shao Shang Za Zhi; 2006 Dec; 22(6):445-7. PubMed ID: 17438692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis.
    Pan CY; Chen JC; Sheen JF; Lin TL; Chen JY
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4264-74. PubMed ID: 24820078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity.
    Deslouches B; Phadke SM; Lazarevic V; Cascio M; Islam K; Montelaro RC; Mietzner TA
    Antimicrob Agents Chemother; 2005 Jan; 49(1):316-22. PubMed ID: 15616311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
    van Delden C
    Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial peptide therapeutics for cystic fibrosis.
    Zhang L; Parente J; Harris SM; Woods DE; Hancock RE; Falla TJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2921-7. PubMed ID: 15980369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice.
    Lee JK; Park SC; Hahm KS; Park Y
    Biomaterials; 2014 Jan; 35(3):1025-39. PubMed ID: 24176194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antimicrobial activity of a synthetic peptide derived from the C-terminal region of human chemokine CCL13 against Pseudomonas aeruginosa.
    Cossio-Ayala M; Domínguez-López M; Mendez-Enriquez E; Portillo-Téllez MDC; García-Hernández E
    Peptides; 2017 Aug; 94():49-55. PubMed ID: 28687455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.